arrow
P

Paul M. Diderichsen

EMD Serono Inc.
H指数:12
被引数:968

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

ATR抑制剂Tuvusertib对实体瘤患者QTc间期影响的综合非临床与临床风险评估

2026-02-100
OAAI
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

整合群体药代动力学、药效动力学和安全性的综合分析,以指导ATR抑制剂Tuvusertib在临床开发中的剂量选择

2025-08-210
OAAI
Use of PopPK and E-R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma-Based Therapies and Clinical Effects in cTTP

利用PopPK和E-R分析解释ADAMTS13在重组疗法与血浆基疗法之间及其与cTTP临床效果之间的因果联系

2025-06-050
OAAI
Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
2023-10-233
OAAI
Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy
2021-09-012
OAAI